Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 16, 2026
Valion Bio, Inc. (VBIO): Can the Stock Reclaim $1.00 After a -97% Drop?

Valion Bio, Inc. (VBIO): Can the Stock Reclaim $1.00 After a -97% Drop?

Key Takeaways

  • Selected price target: $1.00 per share, a psychological and Nasdaq listing-compliance level that implies a roughly 490% gain from the latest close near $0.17.
  • Strongest bullish factors: potential government stockpile procurement for Entolimod, international government interest, and the company's new CDMO subsidiary.
  • Biggest risks: deep losses, meaningful debt, very limited analyst support, potential dilution, and Nasdaq listing risk.
  • Technical levels: support near $0.16; near-term resistance around $0.46–$0.51; major resistance at $1.00, close to the 200-day moving average.
  • Key takeaway: $1 is not impossible for a catalyst-driven biotech, but it currently depends on government contracts and financing events rather than current fundamentals.

Why the $1 Level Matters

$1.00 is more than a round number for this stock. It is the threshold most commonly associated with Nasdaq's minimum bid price listing standard, and it sits near VBIO's 200-day moving average of roughly $1.10. The stock's 52-week range of approximately $0.16 to $5.60 shows that prices above $1 were reachable relatively recently, which keeps the question alive even after the sharp decline. For a sub-$1 stock, reclaiming $1 would also represent a psychological shift out of "penny stock" territory, potentially improving visibility and institutional accessibility.

Company Background

Valion Bio, Inc. is a late-stage biopharmaceutical company formerly known as Tivic Health Systems, Inc.; it changed its name and ticker in April 2026. Its lead candidate, Entolimod, is a Toll-like receptor 5 (TLR5) agonist in late-stage development for acute radiation syndrome (ARS). The program is being advanced under the FDA's Animal Rule pathway, which permits approval based on animal efficacy data when human clinical trials are not feasible. The company is also pursuing oncology supportive care indications and owns Velocity Bioworks, a contract development and manufacturing organization (CDMO). I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Snapshot

The latest verified close put VBIO at $0.1708, with after-hours quotes near $0.17 as U.S. markets remained closed. The company's market capitalization was recently quoted below $1 million, and the stock has been extremely volatile. Financial data show a trailing twelve-month net loss of roughly $13 million, total cash of about $7.2 million, and total debt of about $17.0 million. The most recent book value per share was approximately $3.84, though deeply loss-making micro-cap biotechs rarely trade on book value alone. The 50-day moving average sits near $0.46, reinforcing the scale of the decline from levels that prevailed only weeks ago.

Potential Catalysts for a Recovery

The core bull case is that Entolimod becomes a government-funded medical countermeasure. Valion Bio has described engagement with U.S. agencies including the Biomedical Advanced Research and Development Authority (BARDA), the Defense Threat Reduction Agency (DTRA), and the National Institute of Allergy and Infectious Diseases (NIAID), as well as an international request for information from Ukraine's Ministry of Health. A procurement contract for the U.S. Strategic National Stockpile would be the most important single catalyst; the company has characterized the opportunity as potentially nine-figure and non-dilutive. Additional support could come from CDMO revenue at Velocity Bioworks and clinical progress in chemotherapy-induced neutropenia.

Key Risks to Consider

The obstacles are substantial. No government procurement contract has been announced, and regulatory milestones remain unproven. The company is burning cash, carries meaningful debt, and will likely need additional capital before any commercial inflection arrives, creating dilution risk for current shareholders. Nasdaq listing compliance is another concern for a stock trading well below $1. Visible third-party analyst coverage is extremely thin, and the most prominent aggregated rating has been a sell, meaning the $1 case is currently driven by event speculation and technical psychology rather than published analyst support. From what I see, these factors make any near-term move highly event-dependent.

Important Technical Levels

The most important support zone is the 52-week low near $0.16. Below that, there is little established price history. On the upside, the first meaningful supply zone appears around $0.46 to $0.51, near the 50-day moving average and recent consolidation levels. The decisive test remains $1.00, which aligns with the 200-day moving average and the psychological round-number level. A sustained move toward $1 would require the stock to first reclaim and hold the $0.46–$0.51 area, confirming that the long-term downtrend has reversed. I’m watching this closely as momentum builds or fades around those zones.

Final Assessment

A return to $1.00 appears possible only under a specific, catalyst-heavy scenario: a government stockpile contract or equivalent revenue event, successful regulatory progress for Entolimod, and financing that does not excessively dilute current holders. The strongest supporting factors are the national-security relevance of the lead program and the company's CDMO infrastructure. The primary risks are equally clear: no contract has been signed, losses continue, debt is elevated, and the stock remains in a steep downtrend. Investors should monitor government procurement announcements, cash position and dilution, Nasdaq listing status, and whether VBIO can reclaim the $0.46–$0.51 zone as a first technical step toward any sustainable recovery toward $1.

Integrating AI Tools in Volatile Biotech Names

One resource I turn to for fast-moving situations like this is Tickeron’s AI Daily Buy/Sell Signals. The platform applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals grounded in technical behavior and market conditions. It helps me spot potential shifts in momentum more efficiently while I focus on the underlying catalysts. No signal can forecast binary biotech events, but pairing these outputs with fundamental research has been a practical addition to my routine for names trading at these levels.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: VBIO

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


VBIO in +35.95% Uptrend, growing for three consecutive days on August 24, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where VBIO advanced for three days, in 169 of 197 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Bearish Trend Analysis

The 10-day RSI Indicator for VBIO moved out of overbought territory on August 31, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 25 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Momentum Indicator moved below the 0 level on August 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VBIO as a result. In 83 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for VBIO turned negative on September 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 35 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

VBIO moved below its 50-day moving average on August 31, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for VBIO crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

VBIO broke above its upper Bollinger Band on August 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 70 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.443) is normal, around the industry mean (25.951). P/E Ratio (32.670) is within average values for comparable stocks, (40.223). Projected Growth (PEG Ratio) (0.510) is also within normal values, averaging (9.265). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (436.793).

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. VBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.2B. The market cap for tickers in the group ranges from 58 to 128.84B. VRTX holds the highest valuation in this group at 128.84B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 28%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 8%. PDSB experienced the highest price growth at 112%, while LGVN experienced the biggest fall at -65%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -5%. For the same stocks of the Industry, the average monthly volume growth was -35% and the average quarterly volume growth was -43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 59
SMR Rating: 93
Profit Risk Rating: 92
Seasonality Score: -12 (-100 ... +100)
View a ticker or compare two or three
VBIO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Details
Industry
N/A
Address
1305 East Houston Street
Phone
+1 888 276-6888
Employees
52
Web
N/A
Interact to see
Advertisement
AngloGold Ashanti (AU) shares are tumbling approximately 11% in premarket trading on March 19, 2026, extending a steep multi-week correction that has now erased more than 35% of the stock's value from its March 2 peak of $129.14. The primary sustained catalyst driving the decline is AngloGold's lowered 2026 production guidance, projecting gold output of 2.80–3.17 million ounces — a mid-point decline versus the company's 2025 output of approximately 3.1 million ounces, and below analyst expectations.
CSIQ shares tumbled approximately 18% in premarket trading on March 19, 2026, following the release of deeply disappointing Q4 2025 earnings before the open. The company reported a net loss of $1.66 per diluted share, far worse than the Wall Street consensus estimate of -$0.98, representing a 69% earnings miss.
YRD shares are tumbling approximately 17% in premarket trading on March 19, 2026, from a prior close of $3.68 to approximately $3.05, following the company's release of Q4 and full-year 2025 financial results before the U.S. market open. Primary catalyst: A dramatic swing to net loss in Q4 2025. Yiren Digital reported a Q4 net loss of RMB 882.2 million (~USD 126.1 million), compared to net income of RMB 331.4 million in Q4 2024 — a more than $250 million deterioration year-over-year.
Shares of MU are down approximately 6.66% in premarket trading on March 19, 2026, sliding from a prior close of $461.73 to around $431.00. Despite a historic earnings beat — fiscal Q2 2026 revenue of $23.86 billion versus the $19.19 billion consensus, and adjusted EPS of $12.20 against an $8.79 estimate — the stock is experiencing a classic "sell the news" reaction.
NEM is trading approximately 9% lower in Thursday premarket, extending Wednesday's 4.56% session loss, as gold prices collapse following the Federal Reserve's hawkish policy hold. Gold spot prices fell 4.21% to $4,616.42 per ounce on March 19, marking the precious metal's sixth straight session of declines — its longest losing streak since late 2024.
Shares of VG are surging approximately +8% in Thursday's premarket session on March 19, 2026, with the stock trading near $16.04, up from the March 18 closing price of $14.85. The primary catalyst is a continuation of bullish momentum driven by a series of analyst price target upgrades, with Scotiabank most recently raising its target from $9 to $11.
LINC shares surged approximately +16% in premarket trading on March 19, 2026, reaching roughly $45.83 from a prior close of $39.51. Primary catalyst: Lincoln Educational Services is hosting its highly anticipated Investor Day today at its brand-new Nashville, TN campus, with presentations beginning at 10:00 am CT (11:00 am ET), live-streamed to investors globally.
PSLV is trading approximately 12% lower in premarket on March 19, 2026, tracking a violent selloff in silver futures. The Federal Reserve's hawkish hold on March 18 — keeping rates at 3.50%–3.75% while signaling fewer cuts ahead — was the primary macro trigger.
The Fed kept rates at 3.5–3.75% and signaled a “higher for longer” stance, with no urgency to cut and a willingness to tighten again if inflation stalls. This backdrop tends to favor quality growth, financials, energy, industrials, and health care, while pressuring long‑duration, leveraged sectors like speculative tech, small caps, utilities, and REITs.
PICS shares fell over 20% today, reversing much of their post‑IPO bounce and dropping well below the US$19 IPO price after initially trading in the mid‑US$15–16 range. The selloff followed PicPay’s Q4 and full‑year 2025 results, which showed strong revenue growth but highlighted thin margins, intense competition and ongoing execution risk in credit underwriting and payments.
RCAT shares fell over 16% today, dropping from recent levels near US$17 toward the mid‑US$14–15 range, after trading as high as US$18.78 in the past year and more than tripling from a 52‑week low of US$4.60.
HYMC shares fell over 13% today, sliding from the mid‑US$30s toward roughly US$31, after trading between US$2.30 and US$58.73 over the past 12 months and closing near US$39 just a few sessions ago.
USAS fell over 10% today, trading around US$5.83 by early afternoon from a previous close of US$6.55 — a one‑day decline of roughly 11% — as more than 5.9 million shares changed hands. The stock had surged earlier in 2026, with some data showing a move from about US$1.11 in March 2025 to over US$7.30 in mid‑March 2026 — a gain of more than 500% — leaving it vulnerable to profit‑taking.
CENX fell about 8.9% today, dropping US$4.94 to US$50.40 by midday, after closing at US$55.34 yesterday; shares now sit roughly 15% below their 52‑week high of US$59.12 but remain far above the 12‑month low of US$13.05. Q4 2025 results showed net sales of US$633.7 million and adjusted net income of US$128.2 million (US$1.25 per share), with adjusted EBITDA of US$170.6 million — a big sequential improvement — but GAAP net income was just US$1.8 million (US$0.02 per share), underscoring earnings volatility.
CNL shares fell over 8% today, trading down from around C$22.90 toward the low‑C$21s, after recently setting a new 1‑year high at C$28.99 on March 2 and gaining more than 70% over the past 12 months.
SMCI shares are plunging approximately 26% in Friday premarket trading, extending sharp after-hours losses from Thursday's session close of $30.79. The primary catalyst is a federal indictment unsealed March 19, 2026, charging three individuals associated with Super Micro — including a company co-founder — with conspiring to illegally export billions of dollars in AI server technology to China.
PL shares are surging approximately 19% in premarket trading on March 20, 2026, building on an 8.67% gain during the regular session on March 19. The primary catalyst is a blowout Q4 fiscal year 2026 earnings report released after the close on March 19, with quarterly revenue of $86.8 million — an 11.55% beat against consensus expectations of $77.81 million.
Unusual Machines (UMAC) is trading down approximately -8.60% in premarket on March 20, 2026, extending losses from the prior session. The primary catalyst is a proposed public stock offering announced after the market close on March 19, 2026, raising dilution concerns among investors.
FDX surged approximately 7% in premarket trading on March 20, 2026, moving from the prior session close of $356.11 to around $381. The primary catalyst is a blowout fiscal Q3 2026 earnings report, with adjusted EPS of $5.25 — beating Wall Street's consensus estimate of $4.13 by more than 27%.
Kingsoft Cloud Holdings Limited (KC) shares plunged about 9% in the most recent session, extending a sharp pullback after a recent rally. The selloff reflects mounting concerns around profitability, with the company still loss-making and showing weak multi-year revenue growth.